Targeted Therapy
Approved for: NSCLC
Biomarker: KRAS G12C

Sotorasib is the first treatment for adult patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy.

Related Research News

Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer Outcomes

Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer Outcomes

Long-term study reveals ‘ever-changing’ nature of lung cancer

Long-term study reveals ‘ever-changing’ nature of lung cancer

Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers

Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers